Scientific Resources
MAVDA members now have access to CDD Vault!
The Collaborative Drug Discovery (CDD) Vault is a complete informatics platform hosted through an intuitive interface. It helps project teams manage, analyze, and present data.
Target Product Profiles
The Antiviral Program for Pandemics (APP) team, along with experts from across NIH and BARDA, has drafted Target Product Profiles (TPPs) for potential direct-acting antiviral therapeutics candidates targeting several key viruses of pandemic potential. Realizing that you all are also working on TPPs for these same pathogens, we wanted to share these sample TPPs in case they provide useful tools to supplement your efforts.
TPPs will be available soon on the NIAID APP website.
Open Antivirals
The Open Science Forum is a virtual, public venue to openly share and disseminate antiviral drug discovery research information in a pre-competitive fashion. Guest speakers present target priorities, advertise available resources and reagents, disclose chemical matter (including hits, leads, and chemical tool compounds) and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models, and share ideas. Presentations are recorded and shared publicly online for the benefit of the global antiviral drug discovery community. Learn more.
Protein Constructs Available to MAVDA Members
Protein constructs or clones are available to our MAVDA investigators through our Structural Biology Core. See here for the list of available protein constructs.
Publications
- Small-molecule Inhibition of SARS-CoV-2 Guanine-N7 RNA Cap Methyltransferase
Meyer et al., (Revision; Nature) - SARS-CoV-2-related Bat Viruses Evade Human Intrinsic Immunity but Lack Efficient Transmission Capacity
Peña-Hernández et al., 2024; Nature Microbiology
PMID: 39075235 - Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Biological and Pharmacological Profiling
Alvarez et al., 2024; Viruses
PMID: 39066320; PMCID: PMC11281459 - SARS-CoV-2 Resistance to Monoclonal Antibodies and Small-molecule Drugs
Iketani and Ho., 2024; Cell Chemical Biology
PMID: 38640902; PMCID: PMC11084874 - Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic
Shurtleff et al., 2024; Journal Medicinal Chemistry
PMID: 38365209 - Identifying Structural Features of Nucleotide Analogues to Overcome SARS-CoV-2 Exonuclease Activity
Wang et al., 2022; Viruses
PMID: 35891393; PMCID: PMC9324094 - Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones
Augusto Chaves et al., 2022; Viruses
PMID: 35891437; PMCID: PMC9324382
Patents:
1. The Rockefeller University
Title: “SULFONAMIDE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-
COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF”
Application number: 63/481,410 | Date filed: 1/25/2023 | Type: Therapeutics |
Disease/agent: COVID-19/SARS-CoV-2
Title: “SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2
NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF”
Application number: 63/481,429 | Date filed: 1/25/2023 | Type: Therapeutics |
Disease/agent: COVID-19/SARS-CoV-2
3. The Rockefeller University
Title: “1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3
AND DERIVATIVES THEREOF”
Application number: 63/481,565 | Date filed: 1/25/2023 | Type: Therapeutics |
Disease/agent: COVID-19/SARS-CoV-2
4. Chavez, A., Cha, J. W., Albert, B., Fazekas, C.
Title: “ANTIVIRAL SMALL MOLECULE PROTEASE INHIBITORS”.
Application number: 63/612,311 | Date filed : 12/19/2023 | Status: Patent Pending
5. Chang, CW.
Title: “A NOVEL C3D4 HUMAN CELL MODEL FOR MERS AND SARS-COV-2
INFECTION”
Application number: 63544558 | Status: Provisional Patent application